#Netherlands #Maastricht #CAAS vFFR #Pie Medical Imaging #LIPSIA-STRATEGY

LIPSIA-STRATEGY Trial: A Milestone in Revascularization Techniques

The LIPSIA-STRATEGY trial represents a pivotal advancement in the field of interventional cardiology, showcasing the comparable efficacy of revascularization guided by CAAS vFFR against traditional methods that utilize pressure wires. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference and published in the Journal of the American College of Cardiology (JACC), the results were derived from a comprehensive study that involved 1,053 patients with intermediate coronary stenoses.

Study Design and Objective

The LIPSIA-STRATEGY trial was meticulously designed as a multicenter, randomized clinical trial with the primary aim of assessing whether revascularization guided by CAAS vFFR, which is derived from angiographic imaging, could yield clinical outcomes comparable to those achieved through the conventional pressure wire-guided Fractional Flow Reserve (FFR) approach. Participants were randomly assigned to receive either vFFR-guided or FFR-guided treatment, with major adverse cardiovascular events (MACE) at one year serving as the primary endpoint of the study.

The leadership of this groundbreaking trial came from Prof. Dr. med. Holger Thiele at the Heart Center Leipzig of the University of Leipzig, alongside a network of investigators and study centers. The trial successfully met its primary endpoint, confirming the non-inferiority of the CAAS vFFR-guided treatment strategy.

Key Findings and Implications

Clinical findings from the study revealed that measuring FFR through angiographic methods is less complex than using a pressure wire, yet it produces functionally similar results. As Prof. Dr. med. Holger Thiele noted, “This should become the new standard for managing intermediate coronary stenoses.” Such advancements not only simplify the technical approach but also enhance patient outcomes, ultimately contributing to a more efficient workflow in medical settings.

Bas Kuppens, CEO of Pie Medical Imaging, highlighted the implications of these findings by stating, “The LIPSIA-STRATEGY reinforces the results of FAST III, bolstering clinical evidence for CAAS vFFR while enhancing confidence in our angiography-based physiological solution. With a less invasive workflow, reduced procedure time, and minimized fluoroscopy exposure, these findings draw us closer to making physiology-guided decision-making more accessible in the coronary care continuum—from diagnostic assessment to post-procedural evaluation.”

Conclusion

The trial's results signify a substantial leap forward in the management of coronary artery disease, advocating for the adoption of CAAS vFFR guidance. The ability to perform accurate, non-invasive revascularization procedures will undoubtedly reshape clinical practices, leading to enhanced care and outcomes for patients at risk of cardiovascular events. As Pie Medical Imaging continues to innovate and provide advanced imaging solutions, the potential for significant transformations in how coronary therapies are approached has never been more feasible.

About Pie Medical Imaging

Based in Maastricht, Netherlands, Pie Medical Imaging has established itself as a global leader in advanced cardiovascular imaging analysis, quantification, and visualization solutions. The company champions innovation and is committed to providing software solutions that empower clinicians to improve diagnostics and interventional planning. Pie Medical Imaging adheres to international quality and regulatory standards, ensuring high reliability and absolute clinical trust in its offerings. It operates under the umbrella of the Esaote Group, a leading biomedical equipment provider.

For more information about Pie Medical Imaging and its products, visit www.piemedicalimaging.com.